Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JYP0015 in RAS-mutant advanced solid tumors
NCT06895031Phase 2Recruiting
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of ERAS-0015 in solid tumor, pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), sponsored by Guangzhou JOYO Pharma. Started Mar 2025; status: recruiting.
02
Drugs
ERAS-0015
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06895031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895031.